Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,738

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

Chaudhuri, K Ray, Schapira, Anthony HV·2009·The Lancet Neurology
DOI 10.1016/s1474-4422(09)70068-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(09)70068-7

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 100

  1. 2002, Factors impacting on quality of life in Parkinson's disease: results from an international survey, Mov Disord, 17, 60, 10.1002/mds.10010 · DOI · Paper page
  2. Schrag, 2000, What contributes to quality of life in patients with Parkinson's disease?, J Neurol Neurosurg Psychiatry, 69, 308, 10.1136/jnnp.69.3.308 · DOI · Paper page
  3. Findley, 2003, Direct economic impact of Parkinson's disease: a research survey in the United Kingdom, Mov Disord, 18, 1139, 10.1002/mds.10507 · DOI · Paper page
  4. Hagell, 2002, Resource use and costs in a Swedish cohort of patients with Parkinson's disease, Mov Disord, 17, 1213, 10.1002/mds.10262 · DOI
  5. Chaudhuri, 2008, Quantitation of non-motor symptoms in Parkinson's disease, Eur J Neurol, 15, 2, 10.1111/j.1468-1331.2008.02212.x · DOI · Paper page
  6. Fox, 2008, Non-dopaminergic treatment in development for Parkinson's disease, Lancet Neurol, 7, 927, 10.1016/S1474-4422(08)70214-X · DOI
  7. Naidu, 2008, Early Parkinson's disease and non motor issues, J Neurol, 255, 33, 10.1007/s00415-008-5006-1 · DOI
  8. Wolters, 2006, Parkinson's disease: premotor clinico-pathological correlations, Neural Trans, 70, 309
  9. Politis, 2008, Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride study, Exp Neurol, 214, 112, 10.1016/j.expneurol.2008.07.021 · DOI
  10. Aarsland, 1999, Range of neuropsychiatric disturbances in patients with Parkinson's disease, J Neurol Neurosurg Psychiatry, 67, 492, 10.1136/jnnp.67.4.492 · DOI · Paper page
  11. Aarsland, 2003, Prevalence and characteristics of dementia in Parkinson disease, Arch Neurol, 60, 387, 10.1001/archneur.60.3.387 · DOI · Paper page
  12. Remy, 2005, Depression in Parkinson's disease. Loss of dopamine and noradrenaline innervations in the limbic system, Brain, 128, 1314, 10.1093/brain/awh445 · DOI · Paper page
  13. Corrigan, 2000, Comparison of pramipexole, fluoxetine, and placebo in patients with major depression, Depress Anxiety, 11, 58, 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H · doi:10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
  14. Goldberg, 2004, Prelimimary randomised placebo controlled trial of pramipexole added to mood stabilisers for treatment resistant bipolar depression, Am J Psychiatry, 161, 564, 10.1176/appi.ajp.161.3.564 · DOI · Paper page
  15. Rektorova, 2003, Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study, Eur J Neurol, 10, 399, 10.1046/j.1468-1331.2003.00612.x · DOI · Paper page
  16. Barone, 2006, Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel group randomized study, J Neurol, 253, 601, 10.1007/s00415-006-0067-5 · DOI · Paper page
  17. Reichmann, 2003, Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease, CNS Drugs, 17, 965, 10.2165/00023210-200317130-00003 · DOI
  18. Pahwa, 2007, Ropinirole 24- hour prolonged release: randomized, controlled study in advanced Parkinson disease, Neurology, 68, 1108, 10.1212/01.wnl.0000258660.74391.c1 · DOI · Paper page
  19. Learned-Coughlin, 2003, In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography, Biol Psychiatry, 54, 800, 10.1016/S0006-3223(02)01834-6 · DOI · Paper page
  20. Schmitt, 2002, Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man, J Psychopharmacol, 16, 207, 10.1177/026988110201600303 · DOI
  21. Lemke, 2005, Anhedonia, depression and motor functioning in Parkinson's disease during treatment with pramipexole, J Neuropsychiatry Clin Neurosci, 17, 214, 10.1176/appi.neuropsych.17.2.214 · doi:10.1176/appi.neuropsych.17.2.214
  22. Richard, 1996, Anxiety and Parkinson's disease, J Neuropsychatry Clin Neurosci, 8, 383, 10.1176/jnp.8.4.383 · DOI · Paper page
  23. Kulisevsky, 2006, Acute effects of immediate and controlled release levodopa on mood in Parkinson's disease: a double blind study, Mov Disord, 22, 62, 10.1002/mds.21205 · DOI
  24. Witt, 2008, Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study, Lancet Neurol, 7, 605, 10.1016/S1474-4422(08)70114-5 · DOI · Paper page
  25. Wijtas, 2007, Effects of chronic subthalamic stimulation on non motor fluctuations in Parkinson's disease, Mov Disord, 22, 1729, 10.1002/mds.21602 · DOI · Paper page
  26. Czernecki, 2008, Apathy following subthalamic stimulation in Parkinson's disease: a dopamine responsive syndrome, Mov Disord, 23, 964, 10.1002/mds.21949 · DOI · Paper page
  27. Czernecki, 2002, Motivation, reward and Parkinson's disease: influence of dopa therapy, Neuropsychologia, 40, 2257, 10.1016/S0028-3932(02)00108-2 · DOI · Paper page
  28. Dubois, 1997, Cognitive deficits in Parkinson's disease, J Neurology, 244, 2, 10.1007/PL00007725 · DOI · Paper page
  29. Uc, 2005, Visual dysfunction in Parkinson disease without dementia, Neurology, 65, 1907, 10.1212/01.wnl.0000191565.11065.11 · DOI · Paper page
  30. Williams-Gray, 2007, Evolution of cognitive dysfunction in an incident Parkinson's disease cohort, Brain, 130, 1787, 10.1093/brain/awm111 · DOI · Paper page
  31. Emre, 2003, What causes mental dysfunction in Parkinson's disease?, Mov Disord, 18, S63, 10.1002/mds.10565 · DOI · Paper page
  32. Lewis, 2003, Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry, J Neurosci, 23, 6351, 10.1523/JNEUROSCI.23-15-06351.2003 · DOI · Paper page
  33. Rinne, 2000, Cognitive impairment and the brain dopaminergic system in Parkinson disease—[F-18]fluorodopa positron emission tomographic study, Arch Neurol, 57, 470, 10.1001/archneur.57.4.470 · DOI · Paper page
  34. Cools, 2002, Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET, Brain, 125, 584, 10.1093/brain/awf052 · DOI · Paper page
  35. Mattay, 2002, Dopaminergic modulation of cortical function in patients with Parkinson's disease, Ann Neurol, 51, 156, 10.1002/ana.10078 · DOI · Paper page
  36. Anand, 2007, Safinamide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients, Mov Disord, 22, 797
  37. Ng, 1971, Dopamine stimulation induced release from central neurons, Science, 1172, 487, 10.1126/science.172.3982.487 · DOI
  38. Rye, 2002, Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD, Neurology, 58, 341, 10.1212/WNL.58.3.341 · DOI
  39. Saper, 2001, The sleep switch: hypothalamic control of sleep and wakefulness, Trends Neurosci, 24, 726, 10.1016/S0166-2236(00)02002-6 · DOI · Paper page
  40. Dhawan, 2006, Sleep–related problems of Parkinson's disease, Age Ageing, 35, 220, 10.1093/ageing/afj087 · DOI
  41. Leeman, 1987, Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa, Br J Clin Pharmacol, 24, 637, 10.1111/j.1365-2125.1987.tb03223.x · DOI
  42. Stocchi, 1998, Sleep disorders in Parkinson's disease, J Neurol, 245, S15, 10.1007/PL00007731 · DOI
  43. Van Den Kerchove, 1993, Sustained-release levodopa in parkinsonian patients with nocturnal disabilities, Acta Neurol Belg, 93, 32
  44. Chaudhuri, 1999, The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled-release levodopa, Eur J Neurol, 6, S11
  45. Poewe, 2007, Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double blind, double dummy, randomised controlled trial, Lancet Neurol, 6, 513, 10.1016/S1474-4422(07)70108-4 · DOI · Paper page
  46. Muzerengi, 2006, Restless legs syndrome: a review of diagnosis and management, Int J Sleep Disord, 1, 34
  47. Schapira, 2004, Restless legs syndrome: an update on treatment options, Drugs, 64, 149, 10.2165/00003495-200464020-00003 · DOI
  48. Garcia-Borreguero, 2003, Restless legs syndrome and PD: a review of the evidence for a possible association, Neurology, 61, 49, 10.1212/WNL.61.6_suppl_3.S49 · DOI
  49. Ondo, 2002, Exploring the relationship between Parkinson disease and restless legs syndrome, Arch Neurol, 59, 421, 10.1001/archneur.59.3.421 · DOI · Paper page
  50. Comella, 1994, Akathisia in Parkinson's disease, Mov Disord, 9, 545, 10.1002/mds.870090507 · DOI
  51. Reuter, 1999, Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome, Acta Neurol Scand, 100, 163, 10.1111/j.1600-0404.1999.tb00732.x · DOI · Paper page
  52. Högl, 2003, The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease, Neuropsychopharmacology, 28, 1866, 10.1038/sj.npp.1300250 · DOI
  53. Schenck, 1986, Chronic behavioral disorders of human REM sleep: a new category of parasomnia, Sleep, 9, 293, 10.1093/sleep/9.2.293 · DOI · Paper page
  54. Boeve, 2007, Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease, Brain, 130, 2770, 10.1093/brain/awm056 · DOI · Paper page
  55. Tan, 1996, Rapid eye movement sleep behaviour disorder preceding Parkinson's disease with therapeutic response to levodopa, Mov Disord, 11, 214, 10.1002/mds.870110216 · DOI · Paper page
  56. Iranzo, 2006, Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study, Lancet Neurol, 5, 572, 10.1016/S1474-4422(06)70476-8 · DOI · Paper page
  57. Postuma, 2008, Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behaviour disorder, Neurology
  58. Fantini, 2003, The effects of paramipexole in REM sleep behavior disorder, Neurology, 61, 1418, 10.1212/WNL.61.10.1418 · DOI
  59. Rye, 1998, The pathophysiology of REM sleep behaviour disorder, Sleep, 21, 446
  60. Yamouchi, 2003, Levodopa improved rapid eye movement sleep behaviour disorder with diffuse Lewy body diease, Gen Hosp Psychiatry, 25, 136
  61. Yoshimura, 1992, Dopamine D1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra, Neurourol Urodyn, 11, 535, 10.1002/nau.1930110509 · DOI
  62. Seki, 2001, Role of dopamine D1 and D1 receptors in the micturition reflex in conscious rats, Neurourology Urodyn, 20, 105, 10.1002/1520-6777(2001)20:1<105::AID-NAU12>3.0.CO;2-9 · DOI
  63. Uchiyama, 2003, Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon, Mov Disord, 18, 573, 10.1002/mds.10403 · DOI
  64. Christmas, 1988, Role of subcutaneous apomorphine in parkinsonian voiding dysfunction, Lancet, 2, 1451, 10.1016/S0140-6736(88)90932-4 · DOI
  65. Yoshimura, 1998, Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys, J Pharmacol Exp Ther, 286, 228, 10.1016/S0022-3565(24)37579-2 · DOI
  66. Kuno, 2004, Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients, Parkinsonism Relat Disord, 10, 181, 10.1016/j.parkreldis.2003.08.001 · DOI
  67. Winge, 2004, Effects of dopaminergic treatment on bladder function in Parkinson's disease, Neurourol Urodyn, 23, 689, 10.1002/nau.20054 · DOI
  68. Seif, 2004, Effect of subthalamic deep brain stimulation on the function of the urinary bladder, Ann Neurol, 55, 118, 10.1002/ana.10806 · DOI
  69. Martinez-Martin, 2007, Prevalence of non motor symptoms in Parkinson's disease in an international setting; study using non-motor symptoms questionnaire in 545 patients, Mov Disord, 22, 1623, 10.1002/mds.21586 · DOI · Paper page
  70. Giladi, 2006, Effects of rotigotine transdermal patch on early morning motor function, sleep quality and daytime sleepiness in patients with idiopathic disease. Results of a multicenter, multinational trial (abstract), Eur J Neurol, 13, 74
  71. Metta, 2008, The beneficial effect of rotigotine transdermal patch on nocturia in Parkinson's disease. 6th Intenational Congress on Mental Dysfunctions and Other Non Motor Features in Parkinson's Disease. Dresden, October, 2008, Park Relat Disord
  72. Bronner, 2004, Sexual dysfunction in Parkinson's disease, J Sex Marital Ther, 30, 95, 10.1080/00926230490258893 · DOI · Paper page
  73. Wolters, 2006, Parkinson's disease: premotor premotor clinicopathological correlations, J Neural Trans, 70, 309, 10.1007/978-3-211-45295-0_47 · DOI
  74. Robinson, 1968, Penile erection evoked from forebrain structures in Macaca mulatta, Arch Neurol, 19, 184, 10.1001/archneur.1968.00480020070007 · DOI
  75. Temel, 2004, Deep brain stimulation of the thalamus can influence penile erection, Int J Impot Res, 16, 91, 10.1038/sj.ijir.3901098 · DOI
  76. Moller, 2008, Clinical risk benefit assessment of dopamine agonists, Eur J Neurol, 15, 15, 10.1111/j.1468-1331.2008.02214.x · DOI
  77. Klos, 2005, Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy, Park Relat Disord, 11, 381, 10.1016/j.parkreldis.2005.06.005 · DOI · Paper page
  78. O'Sullivan, 1998, Apomorphine induced penile erections in Parkinson's disease, Mov Disord, 13, 536, 10.1002/mds.870130326 · DOI
  79. Dula, 2001, Double blind crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction, Eur Urol, 39, 558, 10.1159/000052503 · DOI · Paper page
  80. Singharam, 1995, Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation, Lancet, 346, 861, 10.1016/S0140-6736(95)92707-7 · DOI · Paper page
  81. Edwards, 1992, Defecatory function in Parkinson's disease: response to apomorphine, Ann Neurol, 33, 490, 10.1002/ana.410330512 · DOI
  82. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicentre study of effects on non-motor symptoms and quality of life. Mov Disord (in press).
  83. Chudler, 1995, The role of the basal ganglia in nociception and pain, Pain, 60, 3, 10.1016/0304-3959(94)00172-B · DOI · Paper page
  84. Shyu, 1992, Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine induced dopaminergic analgesia, Brain Res, 522, 216, 10.1016/0006-8993(92)90472-L · DOI
  85. Nègre-Pagès, 2008, Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey, Mov Disord, 23, 1361, 10.1002/mds.22142 · DOI · Paper page
  86. Defazio, 2008, Pain as a non motor symptom of Parkinson disease: evidence from a case-control study, Arch Neurol, 65, 1191, 10.1001/archneurol.2008.2 · DOI
  87. Quinn, 1986, Painful Parkinson's disease, Lancet, 1, 1366, 10.1016/S0140-6736(86)91674-0 · DOI · Paper page
  88. Brefel-Courbon, 2005, Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study, Mov Disord, 20, 1557, 10.1002/mds.20629 · DOI · Paper page
  89. Schestatsky, 2007, Neurophysiologic study of central pain in patients with parkinson disease, Neurology, 69, 2162, 10.1212/01.wnl.0000295669.12443.d3 · DOI · Paper page
  90. Djaldetti, 2004, Quantitative measurement of pain sensation in patients with Parkinson disease, Neurology, 62, 2171, 10.1212/01.WNL.0000130455.38550.9D · DOI · Paper page
  91. Loher, 2002, Effect of chronic pallidal deep brain stimulation off period dystonia and sensory symptoms in advanced Parkinson's disease, J Neurol Neurosurg Psychiatry, 73, 395, 10.1136/jnnp.73.4.395 · DOI
  92. Büttner, 1995, Distorted color discrimination in ‘de novo’ parkinsonian patients, Neurology, 45, 386, 10.1212/WNL.45.2.386 · DOI
  93. Postuma, 2006, Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder, Neurology, 66, 845, 10.1212/01.wnl.0000203648.80727.5b · DOI · Paper page
  94. Nguyen-Legros, 1988, Functional neuroarchitecture of the retina: Hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease, Surg Radiol Anat, 10, 137, 10.1007/BF02307822 · DOI
  95. Harnois, 1990, Decreased dopamine in the retinas of patients with Parkinson's disease, Invest Ophtalmol Visual Sci, 31, 2473
  96. Devos, 2005, ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies, Neurology, 65, 1107, 10.1212/01.wnl.0000178896.44905.33 · DOI
  97. Willis, 2008, Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process, Rev Neurosci, 19, 245, 10.1515/REVNEURO.2008.19.4-5.245 · DOI
  98. Wink, 2000, A model of the Parkinsonian visual system: support for the dark adaptation hypothesis, Vision Res, 40, 1937, 10.1016/S0042-6989(00)00036-5 · DOI
  99. Witjas, 2007, Non-motor fluctuations in Parkinson's disease, Rev Neurol, 163, 846, 10.1016/S0035-3787(07)91470-8 · DOI
  100. Stacy, 2005, Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment, Mov Disord, 20, 726, 10.1002/mds.20383 · DOI · Paper page

Cited by

See all 1,738

Metadata

Authors
Chaudhuri, K. R., & Schapira, A. H.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2009-05
Volume
8
Issue
5
Pages
464-474
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(09)70068-7
OpenAlex
W2156411508
Cited by
1,738
References
10
FWCI
45.00
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. https://app.cochat.ai/papers/10.1016/s1474-4422(09)70068-7
The paper
Chaudhuri, K. R., & Schapira, A. H. (2009). Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(09)70068-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.